At-Home Morning Bright Light Treatment for Chronic Nociplastic Pain: Protocol for a Randomized Clinical Trial (Preprint)
Authors:
- Helen J BurgessHBHelen J Burgess
- Allie A RodgersARAllie A Rodgers
- Kiley A McNeilKMKiley A McNeil
- Jackson MottJMJackson Mott
- Agnes FejerAFAgnes Fejer
- Tori DereskiTDTori Dereski
- Muneer RizvydeenMRMuneer Rizvydeen
- Kimberly T SibilleKSKimberly T Sibille
- Hyungjin Myra KimHKHyungjin Myra Kim
- Cherie CofieldCCCherie Cofield
- John W BurnsJBJohn W Burns
- Sana ShaikhSSSana Shaikh
Preprint
- 27 March 2025
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Fibromyalgia, the quintessential nociplastic pain condition, affects more than 20 million Americans and results in significant disability, lost productivity, and poor quality of life, with profound individual and societal cost. As pharmacological treatment approaches offer only modest benefits and result in a high rate of discontinuation due to adverse effects, nonpharmacological interventions such as physical therapy, exercise, and cognitive behavioral therapy are recommended. However, cost and access to these treatments can create barriers to care, and engagement can be problematic. Morning bright light treatment is a promising option for improving fibromyalgia symptoms, with early studies indicating clinically meaningful improvements in fibromyalgia symptoms. OBJECTIVE This study aims to prospectively examine the potential benefits and active elements of morning bright light treatment and sleep timing stabilization for individuals with fibromyalgia in the largest randomized controlled trial to date. METHODS We will recruit 390 adults who meet diagnostic criteria for fibromyalgia and report at least mild symptoms. Participants will be randomized to one of three groups: 4 weeks of morning bright light treatment (1 hour per day, using a commercially available Re-timer device), 4 weeks of sleep timing stabilization alone (a component of morning bright light treatment, some benefit anticipated), or 4 weeks of treatment as usual, with equivalent study contact. Patient-reported outcomes of function and pain will be assessed before and after treatment, with mood, sleep quality, and morningness-eveningness examined as potential mediators of treatment effects. Social determinants of health risk will be examined as a potential moderator influencing baseline symptoms, treatment engagement, and treatment response. RESULTS Data collection began in September 2024 and is projected to end in March 2029. CONCLUSIONS Morning bright light treatment is well-positioned to be an effective nonpharmacological treatment for fibromyalgia with minimal side effects. The study findings will provide important insights relevant to the development of morning bright light treatment as an accessible treatment for chronic nociplastic pain. CLINICALTRIAL ClinicalTrials.gov NCT06567886; https://clinicaltrials.gov/study/NCT06567886 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/75060Keywords
All Related Versions
- Published version: JMIR Research Protocols, 14.
This publication has 74 references indexed in Scilit:
- Greater socioenvironmental risk factors and higher chronic pain stage are associated with thinner bilateral temporal lobesBrain and Behavior, 2023
- Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With FibromyalgiaJAMA Internal Medicine, 2021
- Measures for the Assessment of Pain in AdultsArthritis Care & Research, 2020
- The Area Deprivation Index: A novel tool for harmonizable risk assessment in Alzheimer's disease researchAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- Anticonvulsants for fibromyalgia2013
- Prevalence of the Fibromyalgia Phenotype in Patients With Spine Pain Presenting to a Tertiary Care Pain Clinic and the Potential Treatment ImplicationsArthritis & Rheumatism, 2013
- Prevalence of Fibromyalgia: A Population‐Based Study in Olmsted County, Minnesota, Utilizing the Rochester Epidemiology ProjectArthritis Care & Research, 2012
- Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI‐20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self‐Report Questionnaire (MASQ)Arthritis Care & Research, 2011
- The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom SeverityArthritis Care & Research, 2010
- Bright Light Treatment of Winter DepressionArchives of General Psychiatry, 1998